Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KP0I
|
|||
| Drug Name |
Piperazine carbamate/urea derivative 1
|
|||
| Synonyms |
PMID29334795-Compound-39
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
NOVARTIS AG AUBERSON, Yves BOCK, Mark Gary BRAGA, Dario CURZI, Marco DODD, Stephanie Kay GIAFFREDA, Stefano Luca JIANG, Haiyang KARPINSKI, Piotr TROXLER, Thomas J. WANG, Tielin WANG, Xiaoyang ZHANG, XuechuNOVARTIS AG
|
|||
| Structure |
 |
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H3 receptor (H3R) | Target Info | Ligand | [1] |
| Target's Patent Info | Histamine H3 receptor (H3R) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.